Jubilant Radiopharma and Evergreen Theragnostics have announced a collaboration for the sale and distribution of Neuroendocrine Tumor Diagnostic OCTEVY, pending FDA approval in 2H 2023. Jubilant will prepare, sell, and distribute doses of OCTEVY to PET customers across the US upon regulatory approval. OCTEVY is currently under evaluation by the FDA as a potential radioactive diagnostic agent indicated for use with PET for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
Neuroendocrine tumors, which originate from neuroendocrine cells that transmit messages between the nervous system and endocrine system, are difficult to diagnose due to their heterogeneous symptoms. However, diagnosis rates are increasing, leading to greater demand for accurate imaging options like PET scans. OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), developed by Jubilant Radiopharma and Evergreen Theragnostics as a potential radioactive diagnostic agent for NETs with somatostatin receptors, offers another option for healthcare providers. Pending FDA approval expected in 2H 2023, Jubilant will reconstitute, radiolabel,